A subset of gastric cancer (GC) patients have mutations in genes that participate in or regulate 47
Introduction 69
Gastric cancer (GC) is a common malignancy, ranking in the top 4 of global cancer incidence [1] . 70
Often due to advanced stage diagnosis, gastric cancer patients have a very poor 5-year survival 71 rate [1] . This highlights a desperate need for novel clinical treatments as there are very few 72 approved targeted therapies for GC [2, 3] . Gastric cancer is divided histologically into two groups; 73
intestinal-type and diffuse-type, with intestinal-type being more prevalent. Members of the cell-74 surface Frizzled (Fzd) receptor family are deregulated or overexpressed in several cancer types, 75
including GC [4] . Wnts are lipid-modified glycoproteins that initiate signal transduction by binding 76
to Fzd via a palmitate group, which is appended by the palmitoyltransferase Porcupine (PORCN) 77 [5, 6] . Wnts also bind cell surface co-receptors, such as Lrp5/6, forming a ternary complex [7] . 78
Formation of the Wnt-receptor complex leads to inhibition of a multiprotein 'destruction complex' 79 comprised of Axin, glycogen synthase kinase-3 (GSK3), calcium kinase-1 (CK1) and 80 adenomatous polyposis coli (APC), which targets β-catenin for proteosomal degradation. Newly 81 synthesised cytoplasmic β-catenin can now escape degradation, accumulate and translocate to 82 the nucleus, where it forms a transcriptionally active complex with T-cell factor (TCF)/lymphoid 83 enhancing factor (LEF) family of transcription factors to induce Wnt target gene transcription [8] . 84
However, deregulated Wnt signaling can initiate cell transformation and subsequent 85 carcinogenesis [8] . 86 87 Furthermore, several Wnt/Fzd antagonists [9] are epigenetically silenced through promoter hyper-88 methylation, including DKK3 (67.6% of gastric tumors [10]), sFRP1 (91%), sFRP2 (96%), sFRP5 89 (65%) [11] , whilst others such as the E3 ligase RNF43, which regulates Fzd turnover on the cell 90 surface [12] , are mutated in 54% and 4.8% of microsatellite instable (MSI) and microsatellite 91 stable (MSS) gastric tumors, respectively [13] . Exogenous re-introduction of sFRP or DKK can 92 significantly reduce gastric tumor burden in APC or β-catenin-mutant gastric cancer cells by 93 attenuating Wnt signaling [11, 14] . Critically, this provides proof-of-principle that modulation of 94 ligand/receptor signaling components can further regulate Wnt signaling irrespective of 95 downstream mutations that constitutively activate the pathway, which has been reported in 96 colorectal cancer cells [15] [16] [17] [18] . Together, these data strongly implicate a role for Wnt/Fzd in GC 97 which could be exploited for targeted therapy. 98
99
We recently demonstrated that Frizzled-7 (Fzd7) regulates stem cell function in the gastric and 100
intestinal epithelium [19, 20] . In addition, FZD7 is abundantly expressed in human gastric cancer 101 tissue [21-23], which is also associated with poor patient outcome [24] . Despite compelling 102 evidence implicating Fzd receptors in GC, there has been no formal investigation of the 103 therapeutic benefit of targeting Fzd receptors in GC in vivo. These types of in vivo studies are 104 crucial to fully understand the potential of novel therapeutic strategies due to the complex cellular 105 and molecular interactions of a tumor, which can directly inform clinical trials and cannot be 106 In vivo Cre induction was performed in 8-10 week old mice with a single daily intraperitoneal (ip) 122 injection of 2mg of tamoxifen/mouse/day over four consecutive days. gp130 F/F mice aged 8-9 123 weeks were injected ip with 20mg/kg of OMP-18R5 (OncoMed) or vehicle control 124 (2.5%DMSO+IgG) twice weekly over the course of 30 days at which point animals were sacrificed 125 and tissues harvested. 126 127
Tumor xenografts 128
A total of 4x10 6 cells in 100µl of PBS were injected subcutaneously into the hind flank of 6-8 week 129 old nude mice (nu(ncr)-foxn1 nu/nu). 7 mice were used for each cohort which were treated with 130
Tissue collection and histological analysis 137
Mouse stomachs were isolated, flushed with PBS, fixed overnight at 4°C in 10% neutral buffered 138 formalin (NBF) and processed for immunohistochemistry and immunofluorescence as we 139 previously described [20, 30, 31] , with antibodies used on Table S2 . (Invitrogen) and 1% penicillin/streptomycin (Invitrogen) and L-Glutamine (Invitrogen) and were 168 not taken past passage 15 for experimental use. All cells were tested for Mycoplasma, 169 authenticated and cultured at 37°C in 5% CO2. Gastric cancer cells were transfected with Short-170 hairpin RNA (shRNA) and expression constructs designed to knockdown and stably express 171 FZD7 respectively, as previously described [16, 33] or MSCV-MYC from Addgene (18119). 172 173
Soft agar colony assay 174
Cells were cultured in 60mm tissue culture dishes until 50% confluency and transfected with 5µg 175 of plasmid DNA using Lipofectamine LTX (Invitrogen) following manufacturer's instructions. After 176 48hrs incubation, cells were washed in PBS, detached using trypsin, resuspended 177 RPMI+10%FCS, counted and mixed with pre-warmed 1% agar/RPMI culture medium to a final 178 concentration of 500 cells/well of a 6-well plate. Once agar/cell suspensions solidified, cultures 179
were overlaid with RPMI+10% FCS culture medium and incubated at 37°C in 5% CO2 for 14 days. Table S1 ). To determine if Fzd 248 inhibition could also reduce the growth of antral gastric adenomas in vivo, we treated 8-week-old 249 gp130 F/F mice, which at this age have small antral gastric adenomas ( Supplementary Fig. S2E) , 250
with OMP-18R5 twice a week for 30 days, following published protocols ( Supplementary Fig. S3A ) 251 
Conditional deletion of Fzd7 from gp130 F/F gastric tumors reduces cell proliferation 285
To determine the functional requirement of Fzd7 for gastric adenoma growth in vivo, we 286 conditionally deleted Fzd7 in the gastric adenomas of 8-week old Tff1Cre ERT2/+ ;gp130 F/F ;Fzd7 fl/fl 287 mice (Cre + ;gp130 F/F ;Fzd7 fl/fl ) ( Supplementary Fig. S4C ), which allows robust recombination in 288 that Fzd7 deleted cells are retained in these adenomas (Fig. 4C) . In support, the expression of 306
Fzd7 and many Wnt pathway components and target genes remain low in these adenomas ( Fig.  307 4D, Supplementary Fig. S4E and Table S1 ). This suggests that the mechanism underlying smaller 308 gastric adenomas following Fzd7 deletion is due to retention of Fzd7-deficient cells in the 309 adenoma that are unable to respond to proliferative Wnt signals, and thus fail to proliferate (Fig.  310   4E) . To investigate this further, we performed IHC on serial sections to detect recombined (β-gal + , 311 This also suggests that gastric adenomas do not repopulate following Fzd7 deletion, as 320 repopulation in the normal gastric epithelium following Fzd7 deletion is associated with reduced 321 cell differentiation [19] . No change in the frequency of Caspase-3 + cells was observed 322 ( Supplementary Fig. S4D ), indicating that deletion of Fzd7 from adenoma cells does not trigger 323
apoptosis. 324 325

Cell intrinsic Wnt signaling via Fzd7 is required for Wnt-driven gastric adenomas 326
The gp130 F/F mice and MKN45 GC cells are wild-type for APC, and have no known Wnt-activating 327 mutations, suggesting that targeting Fzd7 may be effective in gastric adenomas and GC cells 328 without mutations to the Wnt pathway. However, some of the GC cell lines that responded to Fzd 329 therapy (MKN28 and MKN74) have mutant APC (https://portals.broadinstitute.org/ccle), 330
suggesting that Fzd therapies can be effective in gastric adenomas with and without mutant APC. 331
In silico analysis of GC patient datasets identify mutations in several genes that regulate Wnt 332 signaling, demonstrating that this pathway is aberrantly activated in GC ( Supplementary Fig.  333 S5A). To functionally investigate this, gastric organoids established from Tff1Cre ERT2/+ ;Apc fl/fl 334 (Cre + ;Apc fl/fl ) mice were treated with tamoxifen, to truncate Apc, and showed significant increase 335 in growth and proliferation (Fig. 5A) , which was confirmed by Ki-67 staining and increased cell 336 viability (MTT assay) (Figs. 5A-C). A concordant increase in Wnt target gene expression was 337 observed in hyperproliferative Apc mutant organoids (Fig. 5D ). Treatment of Apc mutant 338 organoids with IWP-2 or OMP-18R5 prevented upregulation of the Wnt pathway and blocked 339 organoid proliferation (Figs. 5A-D), demonstrating that cell intrinsic Wnt secretion and Fzd 340 receptors are required for gastric cells to activate Wnt signaling and regulate growth, even after 341 mutation of Apc (Figs. 5A-D) . 342
343
Fzd7 expression was increased in Apc mutant gastric organoids and subsequently downregulated 344 in IWP-2 or OMP-18R5 treated organoids (Fig. 5E ), therefore we examined whether Fzd7 is 345 responsible for transmitting Wnt signaling in Apc mutant gastric adenoma cells in vivo. 30 days 346 following tamoxifen, Cre + ;Apc fl/fl mice developed multiple, large intestinal-type gastric adenomas 347 with extensive hyperplasia in the antral stomach ( Figs. 6A and B) , which were not observed in 348 tamoxifen-treated Cre -;Apc fl/fl mice (Fig. 6A) . Remarkably, co-recombination of Apc and as monitored by expression of the Fzd7 Δ allele (Fig. 6D) . Myc ( Supplementary Fig. S6A ). IHC revealed a decrease in Muc5a + and Gastrin + cells following 359
Apc mutation ( Supplementary Fig. S6B ), while tamoxifen-treated Cre + ;Apc fl/fl ;Fzd7 fl/fl mice display 360 a modest restoration of mucus-secreting and gastrin-producing cells, similar to that observed in 361 Cre + ;gp130 F/F ;Fzd7 fl/fl mice ( Supplementary Fig. S4D ). Collectively, these data demonstrate that 362
Apc-mutant gastric phenotypes require functional Fzd7. Supplementary Fig. S7 ), indicating Fzd7-dependant expression of Myc is 372 required for the growth of Apc mutant gastric adenomas. 373
To determine whether elevated levels of MYC can rescue GC cell growth suppression following 374 FZD7 knockdown, GC cells were co-transfected with FZD7shRNA and MSCV-MYC expression 375 plasmids and grown as colonies in soft agar for 2 weeks. Compared to control (EV) transfected 376 cells, co-transfected cells (FZD7shRNA and MSCV-MYC) showed no difference in the number of 377 colonies formed ( Supplementary Fig. S7G-I) , which suggests that overexpression of MYC is able 378 to rescue the growth suppressive effects of FZD7 knockdown in GC cells. In vitro studies have shown that targeted inhibition of Fzd is sufficient to block growth of GC cells 387
[24, 44]. However, it is well documented that in vitro studies do not fully recapitulate the complex 388 cellular and molecular interactions present in tumors [45] . Here, we demonstrate that gastric 389 adenomas require Fzd7 for optimal growth using genetic and pharmacological strategies in two 390 independent mouse models. Our findings support our previous work [39] demonstrating that 391 targeting multiple Fzd receptors blocks the growth of several different cancers, which we now 392 extend to GC. Using ex-vivo adenoma-derived organoids we demonstrate these anti-growth 393 effects are cell intrinsic as OMP-18R5 blocks the growth of gastric adenoma-derived organoids in 394 the absence of immune or stromal cells. 395
396
As previously observed in the normal gastric epithelium [19] , genetic inhibition of Fzd7 in gastric 397 adenomas induces upregulation of other Fzd genes (Table S1) , however, these are insufficient to 398 compensate and promote gastric adenoma growth. This suggests that specific targeting of Fzd7 399 is an attractive therapeutic strategy for the treatment of gastric cancer. is an effective tissue mechanism that helps the gastric epithelium to survive the harsh conditions 404 of the stomach. Here we show that repopulation is not preserved in gastric adenomas, which 405 contain aberrant cell signaling and tissue architecture, and therefore Fzd7-deficient cells remain 406 in the adenoma but are unable to respond to Wnt signals and thus do not proliferate. 407
One feature of inflammation-associated tumors in the gastrointestinal tract is phosphorylated 408 Importantly, these genomic studies are yet to be validated with functional interrogation in vivo, 420
which are essential to understand the therapeutic potential of targeting Wnt signaling in gastric 421 cancer [21] . We and others have demonstrated that Fzd7 inhibition is sufficient to block Wnt 422 signaling in cells with mutant APC [17, 51]. Interestingly, ~37% of APC mutant gastric tumors are 423 mutant for RNF43 (regulates Fzd on the cell surface [12]), demonstrating that Fzd is deregulated 424 in a subset of APC mutant gastric tumors (http://www.cbioportal.org/). Interestingly RNF43 and 425 APC mutations are mutually exclusive in colon tumors suggesting that CRC and GC cells 426 preferentially select different Wnt mutations that confer optimal or 'just-right' levels of Wnt 427 signaling required for tumor growth [52, 53] . 428 429 Furthermore, we have shown that Myc is required for the gastric adenoma phenotypes associated 430
with Apc mutation. These findings are reminiscent of the role played by Myc in the intestinal 431 epithelium following Apc mutation [35] , and thus place the Wnt/Fzd7/Myc signaling axis as an 432 attractive therapeutic target for gastric cancer. Encouragingly, next generation bromodomain 433 (BET) inhibitors are effective in killing patient-derived GC cells [54] . Importantly, this provides 434 justification for testing a combination of BET and Wnt inhibitors in GC, which we have previously 435
shown is effective at blocking the growth of human colon cancer cells [55] . 436 437 New generation PORCN inhibitors are in clinical trials for solid tumors, which our results show 438 may be effective in gastric cancer, however these target the secretion of all Wnt ligands. 439
Collectively, we demonstrate that targeted inhibition of Wnt receptors, specifically Fzd7, is rate-440 limiting for the growth of gastric adenomas with and without Apc mutations. This provides a broad 441 scope for the application of this therapeutic strategy for the treatment of GC, with potentially less 442 side effects than targeting all Wnt secretion with PORCN inhibitors, and will directly inform clinical 443 trials to treat GC patients with OMP-18R5 (Vantictumab), which only targets 5 out of the 10 Fzd 
